A-Share Buyback Wave Accelerates as BOE Technology, Shenyang Xingqi Pharmaceutical and Other Leaders Push Ahead

Corporate Action
โดย 证券时报·Read original
Summary · why it matters

The A-share buyback wave is accelerating, with multiple industry leaders intensively disclosing progress. Panel leader BOE Technology had repurchased 500 million yuan of A-shares by July 31, reaching the lower limit of its buyback plan, taking only about half a month since the first repurchase on July 20. The company also simultaneously repurchased B-shares for 393 million Hong Kong dollars, shortly after completing a round of over 4 billion yuan in A-share buybacks at the end of May. Eye drug leader Shenyang Xingqi Pharmaceutical completed its 80 million to 100 million yuan buyback plan in just about a week, with the payment amount reaching 100 million yuan as of August 4. Innovative drug leader Hengrui Medicine had cumulatively paid 853 million yuan for buybacks as of July 31, while dental service leader Topchoice Medical's buyback amount reached 88.75 million yuan in the same period, approaching 90 percent of the 100 million yuan plan cap.

Impact on stocks 4

Others▲ · 4 stocks
BOE Technology Group Co Ltd
000725
▲ PositiveCapitalrelevance

BOE Technology repurchased 500 million yuan of A-shares and 393 million Hong Kong dollars of B-shares, reaching the lower limit of its buyback plan.

Shenyang Xingqi Pharmaceutical Co Ltd
300573
▲ PositiveCapitalrelevance

Shenyang Xingqi Pharmaceutical completed its 80-100 million yuan buyback plan in about a week, with payment reaching 100 million yuan as of August 4.

Jiangsu Hengrui Medicine Co Ltd
600276
▲ PositiveCapitalrelevance

Hengrui Medicine has cumulatively paid 853 million yuan for buybacks as of July 31, indicating strong capital return to shareholders.

© 2026 MarketDXNews